BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 18, Issue 3
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 115679
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.115679
Figure 7
Full Size Figure Download Figure
Figure 7 Graphical abstract demonstrating how CD44 knockout inhibits pancreatic cancer cell tumorigenesis and is a new option for targeted therapy in pancreatic cancer. CD44 knockout inhibited pancreatic cancer cell tumorigenesis, migration, and invasion, and suppressed tumor growth in vivo by reducing the expression levels of oncogenic X-inactive-specific transcript and various other tumorigenic genes and diminishing the tumorigenic AKT and ERK signaling pathways. On the other hand, CD44 knockout activated the tumor-suppressive p38-p53 signaling pathway, increased pancreatic cancer cell DNA damage, and enhanced cell vulnerability to the anti-cancer drug cisplatin. These data highlight that CD44 is required for pancreatic cell tumorigenesis and suggest that CD44 knockout is a new option for targeted therapy in pancreatic cancer.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.